Biogen (NASDAQ:BIIB) has finally submitted a biologics license application (BLA) for aducanumab, a monthly infusion that prevents amyloid plaques from forming in the brain.Biogen ran a pair of pivotal studies with aducanumab, only one of which measured a significant benefit with regard to patients' dementia ratings after treatment with the highest dose tested.